Clinical Research Director at Merck Research Laboratories.
European Commission Approves Merck's Capvaxive for Adult Pneumococcal Disease Prevention
New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.
Read More
Capvaxive’s EU Approval and Impact on Pneumococcal Disease Prevention: A Focus on At-Risk Populations
Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.